Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)
NCT ID: NCT02881099
Last Updated: 2024-11-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2614 participants
OBSERVATIONAL
2011-11-13
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary objective: To define the severity and rates of progression of clinical features of Parkinson's Disease.
Secondary objective: To relate clinical phenomenology of Parkinson's disease to genetic and biomarker changes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Recent diagnosis (P3)
Primary cohort; participants recruited if diagnosed within the last three years
No interventions assigned to this group
Early diagnosis (P50)
Participants recruited if diagnosed before the age of 50 years old
No interventions assigned to this group
Relatives (R)
Siblings of existing participants
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age ≥18 to \<90years
3. Subject is able and willing to provided informed consent.
1. Age ≥18 to \< 90years
2. Resident in the United Kingdom and able to access one of the PRoBaND study centres.
3. Subject is able and willing to provided informed consent.
Exclusion Criteria
2. Patient has features indicating another type of degenerative parkinsonism, e.g. progressive supranuclear palsy
3. Drug-induced parkinsonism (Drug-unmasked PD is allowed)
4. Symmetrical lower body parkinsonism attributable to significant cortical and/or subcortical cerebrovascular disease (patients with 'incidental' small vessel disease on brain imaging are allowed).
5. Negative or normal functional imaging of the presynaptic dopamine system
1. Subject has severe comorbid illness that would prevent study participation
2. Subject already has a diagnosis of Parkinson's disease
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Parkinson's UK
OTHER
University of Bristol
OTHER
Cardiff University
OTHER
University of Glasgow
OTHER
South Glasgow University Hospitals NHS Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr Donald Grosset
Senior Research Fellow
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Donald Grosset, BSc, MD
Role: STUDY_DIRECTOR
University of Glasgow
References
Explore related publications, articles, or registry entries linked to this study.
Malek N, Weil RS, Bresner C, Lawton MA, Grosset KA, Tan M, Bajaj N, Barker RA, Burn DJ, Foltynie T, Hardy J, Wood NW, Ben-Shlomo Y, Williams NW, Grosset DG, Morris HR; PRoBaND clinical consortium. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. J Neurol Neurosurg Psychiatry. 2018 Jul;89(7):702-709. doi: 10.1136/jnnp-2017-317348. Epub 2018 Jan 29.
Swallow DM, Lawton MA, Grosset KA, Malek N, Klein J, Baig F, Ruffmann C, Bajaj NP, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Morris HR, Williams N, Wood NW, Hu MT, Grosset DG. Statins are underused in recent-onset Parkinson's disease with increased vascular risk: findings from the UK Tracking Parkinson's and Oxford Parkinson's Disease Centre (OPDC) discovery cohorts. J Neurol Neurosurg Psychiatry. 2016 Nov;87(11):1183-1190. doi: 10.1136/jnnp-2016-313642. Epub 2016 Sep 26.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GN11NE062
Identifier Type: -
Identifier Source: org_study_id